An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of ...

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Many eye conditions can be easily treated if those at risk undergo regular eye examinations, and are informed about good ...

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report), retaining the price target of ...